As advised via PHARMAC Tender Results of 30 September 2019 there is to be a change in the listing and future sole supply of capecitabine.

New listing from 1 February 2020

Capercit Dr Reddy’s Tab 150 mg 60 blister pack                Pharmacode TBA                                    Schedule price $10.00

Capercit Dr Reddy’s Tab 500 mg 120 bliste pack               Pharmacode TBA                                    Schedule price $49.00

Incumbent brand

Brinov Tab 150 mg 60 blister pack                                         Pharmacode 2494116                         Schedule price $11.15

Brinov Tab 500 mg 120 blister pack                                       Pharmacode  2494124                       Schedule price $62.28

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 July 2020.

Brand switch fee for Community Pharmacy not advised in notification.

As of the date of this notification ProPharma / PWR cannot accept Brinov Tablets for credit under any circumstances.

From 1 February 2020 community pharmacies dispensing Capecitabine will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Benefit of staying with incumbent while stock remains available are as follows based on pack dispensing, keeping in mind every cent counts:-

150 mg : – 1 x 60 Brinov Tab 150 mg  @ $11.15 x 3% = $0.3345 plus $0.255 (pack fee) giving you $0.5895

Compared to $10.00 x 3% = $0.3000 plus $0.255 (pack fee) giving you $0.5550

500 mg : – 1 x 120 Brinov Tab 500 mg @ $62.28 x 3% = $1.8684 plus $0.255 (pack fee) giving you $2.1234

Compared to $49.00 x 3% = $1.4700 plus $0.255 (pack fee) giving you $1.7250

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 July 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 July 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author